Real-World Effectiveness and Safety of Selective JAK Inhibitors in Ulcerative Colitis and Crohn’s Disease A Retrospective, Multicentre Study /
Background/Objectives: Data on the real-world effectiveness and safety of selective JAK inhibitors (JAKis) in ulcerative colitis (UC) and Crohn’s disease (CD) are limited. Methods: We conducted a multicentre, retrospective study to assess clinical, biochemical, and endoscopic outcomes of selective J...
Elmentve itt :
| Szerzők: | |
|---|---|
| Dokumentumtípus: | Cikk |
| Megjelent: |
2024
|
| Sorozat: | JOURNAL OF CLINICAL MEDICINE
13 No. 24 |
| Tárgyszavak: | |
| doi: | 10.3390/jcm13247804 |
| mtmt: | 35648124 |
| Online Access: | http://publicatio.bibl.u-szeged.hu/35449 |
| LEADER | 03740nab a2200565 i 4500 | ||
|---|---|---|---|
| 001 | publ35449 | ||
| 005 | 20250104185227.0 | ||
| 008 | 250104s2024 hu o 000 eng d | ||
| 022 | |a 2077-0383 | ||
| 024 | 7 | |a 10.3390/jcm13247804 |2 doi | |
| 024 | 7 | |a 35648124 |2 mtmt | |
| 040 | |a SZTE Publicatio Repozitórium |b hun | ||
| 041 | |a eng | ||
| 100 | 1 | |a Farkas Bernadett | |
| 245 | 1 | 0 | |a Real-World Effectiveness and Safety of Selective JAK Inhibitors in Ulcerative Colitis and Crohn’s Disease |h [elektronikus dokumentum] : |b A Retrospective, Multicentre Study / |c Farkas Bernadett |
| 260 | |c 2024 | ||
| 300 | |a 19 | ||
| 490 | 0 | |a JOURNAL OF CLINICAL MEDICINE |v 13 No. 24 | |
| 520 | 3 | |a Background/Objectives: Data on the real-world effectiveness and safety of selective JAK inhibitors (JAKis) in ulcerative colitis (UC) and Crohn’s disease (CD) are limited. Methods: We conducted a multicentre, retrospective study to assess clinical, biochemical, and endoscopic outcomes of selective JAKis in bio-experienced UC and CD. Results: A total of 246 patients (mean age: 40.5 ± 14.5 years; 131 UC and 115 CD) were included with a median follow-up of 7.5 months. Among the CD patients receiving upadacitinib (n = 115), 76.2% achieved clinical remission (CR) at week 12. Furthermore, 59.5% of the upadacitinib-treated UC patients (n = 100) experienced CR at week 8. Corticosteroid-free CR (CSFCR) was achieved by 76.9% of the CD patients and 80.6% of the UC patients at week 24, while 50.0% and 36.1% experienced endoscopic remission. At week 52, 66.7% of the CD and 86.2% of the UC patients achieved CSFCR, whereas 54.5% and 52.9% had endoscopic remission. In UC, the effectiveness of upadacitinib was not compromised by prior tofacitinib failure, while the upadacitinib-treated CD patients with stricturing and penetrating disease were less likely to achieve CR by the end of the induction phase (p = 0.04). C-reactive protein (p[CD] < 0.0001; p[UC] < 0.0001) and faecal calprotectin (p[CD] < 0.0001; p[UC] = 0.02) decreased significantly in both patient groups as early as week 2. Among the filgotinib-treated UC patients (n = 31), 28.6% were in CR at week 12. At week 24 and 52, 59.1% and 60% achieved CSFCR, while 0.0% and 20.0% had endoscopic remission. Both C-reactive protein (p = 0.04) and faecal calprotectin (p = 0.04) decreased significantly by week 12. Hyperlipidaemia (9.7–9.8%) was the most common adverse event. Conclusions: Selective JAKis are rapidly effective and safe for treating refractory, moderate-to-severe CD and UC. | |
| 650 | 4 | |a Gasztroenterológia és hepatológia | |
| 700 | 0 | 1 | |a Bessissow Talat |e aut |
| 700 | 0 | 1 | |a Limdi Jimmy K. |e aut |
| 700 | 0 | 2 | |a Sethi-Arora Karishma |e aut |
| 700 | 0 | 2 | |a Kagramanova Anna |e aut |
| 700 | 0 | 2 | |a Knyazev Oleg |e aut |
| 700 | 0 | 2 | |a Bezzio Cristina |e aut |
| 700 | 0 | 2 | |a Armuzzi Alessandro |e aut |
| 700 | 0 | 2 | |a Lukas Milan |e aut |
| 700 | 0 | 2 | |a Michalopoulos George |e aut |
| 700 | 0 | 2 | |a Chaskova Elena |e aut |
| 700 | 0 | 2 | |a Savarino Edoardo Vincenzo |e aut |
| 700 | 0 | 2 | |a Castiglione Fabiana |e aut |
| 700 | 0 | 2 | |a Rispo Antonio |e aut |
| 700 | 0 | 2 | |a Schäfer Eszter |e aut |
| 700 | 0 | 2 | |a Saibeni Simone |e aut |
| 700 | 0 | 2 | |a Filip Rafal |e aut |
| 700 | 0 | 2 | |a Attauabi Mohamed |e aut |
| 700 | 0 | 2 | |a Fousekis Fotios S. |e aut |
| 700 | 0 | 2 | |a Bacsur Péter |e aut |
| 700 | 0 | 2 | |a Resál Tamás |e aut |
| 700 | 0 | 2 | |a Bálint Anita |e aut |
| 700 | 0 | 2 | |a Ivány Emese |e aut |
| 700 | 0 | 2 | |a Szepes Zoltán |e aut |
| 700 | 0 | 2 | |a Bősze Zsófia |e aut |
| 700 | 0 | 2 | |a Fábián Anna |e aut |
| 700 | 0 | 2 | |a Bor Renáta |e aut |
| 700 | 0 | 2 | |a Farkas Klaudia |e aut |
| 700 | 0 | 2 | |a Lakatos Péter László |e aut |
| 700 | 0 | 2 | |a Molnár Tamás |e aut |
| 856 | 4 | 0 | |u http://publicatio.bibl.u-szeged.hu/35449/1/jcm-13-07804-v2.pdf |z Dokumentum-elérés |